Ann Dermatol.  2019 Oct;31(5):591-593. 10.5021/ad.2019.31.5.591.

Pseudomyogenic Hemangioendothelioma in a 30-Year-Old Man: A Rare Case Report

• Liao CY
• Juan CK
• Yang CS
• Chen YJ

• KMID: 2456242
• DOI: http://doi.org/10.5021/ad.2019.31.5.591

Abstract

No abstract available.

MeSH Terms

Adult*
Hemangioendothelioma*
Humans

Figure

• 

  Fig. 1 (A) Solitary painful erythematous indurated plaque with overlying crust and ulcer on right radial side of forearm. (B) Multiple tender erythematous subcutaneous nodules with overlying crust over periungal region over 3rd finger. (C) Computed tomography of right forearm shows several enhanced nodule up to 3.4 cm in flexor digitorum superficialis muscle, flexor digitorum profundus muscle, flexor carpi ulnaris muscle, extensor carpi radialis brevis muscle and in subcutaneous region over ulnar side.

• 

  Fig. 2 (A) Infiltrative intradermal to subcutical tumor mass with proliferative spindle cells and inflammatory cell infiltration (haematoxylin and eosin [H&E], ×100). (B) Fasicles of interlacing spindle cells and brisk inflammatory cell scattered among the tumor cell. Red blood cell extravasation is also seen (H&E, ×200). (C) Plumped spindle cell with vesicular nucleus, prominent nucleoli and ample eosinophilic cytoplasm. Mitotic figure and pleomorphism are inconspicuous (H&E, ×400). (D) Immunohistochemistry staining showed diffuse positive staining for AE1/AE3 (×200), (E) erythroblastosis virus E26 transforming sequencerelated gene (×200), (F) CD31 (×200), (G) friend leukemia integration 1 transcription factor (×200), (H) integrase interactor 1 (×200), and (I) negative staining for CD34 (×200).

Reference

1. Raftopoulos E, Royer M, Warren M, Zhao J, Rush W. Pseudomyogenic hemangioendothelioma: case report and review of the literature. Am J Dermatopathol. 2018; 40:597–601. PMID: 29406432.

2. Horan NA, DiMaio DJ. Pseudomyogenic hemangioendothelioma. Cutis. 2017; 100:E13–E16.

3. van IJzendoorn DGP, Sleijfer S, Gelderblom H, Eskens FALM, van Leenders GJLH, Szuhai K, et al. Telatinib is an effective targeted therapy for pseudomyogenic hemangioendothelioma. Clin Cancer Res. 2018; 24:2678–2687. PMID: 29511030.

4. Gabor KM, Sapi Z, Tiszlavicz LG, Fige A, Bereczki C, Bartyik K. Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. Pediatr Blood Cancer. 2018; 65:e26781.

5. Requena L, Santonja C, Martinez-Amo JL, Saus C, Kutzner H. Cutaneous epithelioid sarcomalike (pseudomyogenic) hemangioendothelioma: a little-known low-grade cutaneous vascular neoplasm. JAMA Dermatol. 2013; 149:459–465. PMID: 23715533.